Pre-clinical evaluation of novel targets against cardiomyopathies
- Universitätsklinikum Heidelberg
- Patrick Most
Unmet clinical needs such as heart failure or Cor pulmonale fuel our interest in pharmacological strategies that improve cardiac performance by bypassing cAMP signaling and extend to the mitigation of tachyarrhythmia susceptibility, energy defects and adverse remodeling. To this end, this project seeks to determine therapeutic efficacy and safety/toxicology of S100A1 synthetic peptide- (working package 1a/b) and in vitro transcribed mRNA-based (working package 2a/b) experimental therapies against disorders of the left and right ventricular chambers in in vitro and in vivo models.
- Peptide- and mRNA-based therapeutic molecules, heart failure, Cor pulmonale
- DNA/RNA based, protein based therapy
- € 556.221,82